These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 209810)

  • 21. Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.
    Urtasun RC; Band P; Chapman JD; Rabin HR; Wilson AF; Fryer CG
    Radiology; 1977 Mar; 122(3):801-4. PubMed ID: 841074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The response of human tumour metastases to radiation and misonidazole.
    Dawen PJ; Peckham MJ; Steel GG
    Br J Cancer Suppl; 1978 Jun; 3():290-6. PubMed ID: 277247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole.
    Coleman CN; Friedman MK; Jacobs C; Halsey J; Ignoffo R; Leibel S; Hirst VK; Gribble M; Carter SK; Phillips TL
    Cancer Res; 1983 Oct; 43(10):5022-5. PubMed ID: 6883348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of misonidazole on formation of thymine damage by gamma rays.
    Remsen JF
    Radiat Res; 1985 Feb; 101(2):306-11. PubMed ID: 3975359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
    Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Noll L; Hancock S; Phillips TL
    Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.
    Dische S; Saunders MI; Lee ME; Adams GE; Flockhart IR
    Br J Cancer; 1977 May; 35(5):567-79. PubMed ID: 861146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
    Schwade JG; Makuch RW; Strong JM; Glatstein E
    Cancer Treat Rep; 1982 Sep; 66(9):1743-50. PubMed ID: 6288238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Radiosensitizer: hypoxic cell radiosensitizer].
    Mori T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1399-404. PubMed ID: 2525001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary results of RTOG phase I/II study of misonidazole and radiation for bladder cancer.
    Mohiuddin M; Kramer S; Phillips T; Soberon M; Forgione H
    Am J Clin Oncol; 1982 Oct; 5(5):551-4. PubMed ID: 7180834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical evaluation of hypoxic cell sensitizer (Misonidazole)].
    Asakawa H; Watarai J; Hoshino T
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1225-30. PubMed ID: 6732250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Development of new hypoxic cell radiosensitizer in Japan].
    Mori T; Murayama C
    Gan No Rinsho; 1988 Oct; 34(13):1869-74. PubMed ID: 2974089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiosensitization in multifraction schedules. II. Greater sensitization by 2-nitroimidazoles than by oxygen.
    Taylor YC; Brown JM
    Radiat Res; 1987 Oct; 112(1):134-45. PubMed ID: 3659294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical trials of hypoxic cell sensitizer misonidazole].
    Onoyama Y
    Gan No Rinsho; 1983 May; 29(6):718-25. PubMed ID: 6348345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Misonidazole neuropathy.
    Paulson OB; Melgaard B; Hansen HS; Kamieniecka Z; Køhler O; Hansen JM; Pedersen AG; Tang X; Trojaborg W
    Acta Neurol Scand Suppl; 1984; 100():133-6. PubMed ID: 6091392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of hypoxic cell radiosensitizers: a review.
    Workman P
    Cancer Clin Trials; 1980; 3(3):237-51. PubMed ID: 7438321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A preliminary clinical study in the use of misonidazole in cancer of the head and neck.
    Sealy R
    Br J Cancer Suppl; 1978 Jun; 3():314-7. PubMed ID: 277253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.
    Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Hirst VK; Hancock S; Phillips TL
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1105-8. PubMed ID: 3017904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of misonidazole in combination with radiation dose fractionation.
    Hill RP; Bush RS
    Br J Cancer Suppl; 1978 Jun; 3():255-8. PubMed ID: 277242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical experiences with the radiation-sensitizing agent misonidazole].
    Kogelnik HD; Szepesi T; Kärcher KH; Seitz W
    Strahlentherapie Sonderb; 1978; 75():115-9. PubMed ID: 162327
    [No Abstract]   [Full Text] [Related]  

  • 40. A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.
    Roberts JT; Bleehen NM; Workman P; Walton MI
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1755-8. PubMed ID: 6480458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.